The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: A Danish population‐based cohort study
Abstract
BACKGROUND: Tamoxifen therapy is reported to increase the risk of deep venous thrombosis and pulmonary embolism (DVT/PE). To the authors' knowledge, it is not yet known whether the risk changes with the amount of time elapsed since the initial tamoxifen prescription. This information would be valuable in identifying patients at high risk for DVT/PE. METHODS: The relation between timing of tamoxifen use and venous thromboembolism risk was examined. The study population of 16,289 women was identified from the clinical database of the Danish Breast Cancer Cooperative Group. It included women diagnosed with International Union Against Cancer (UICC) stage I or stage II estrogen receptor‐positive breast cancer between 1990 and 2004 at ages 45 to 69 years. Risks, risk ratios (RRs), and crude and adjusted hazards ratios were calculated for each of the first 5 years after breast cancer surgery and then cumulatively over the next 5 years. RESULTS: The 5‐year risk of DVT/PE was 1.2% for women receiving tamoxifen and 0.50% for women not receiving tamoxifen. Women treated with tamoxifen were at a higher risk for DVT/PE during the first 2 years after exposure (RR, 3.5; 95% confidence interval [95% CI], 2.1‐6.0). Subsequently, their risk was not found to be substantially increased (RR, 1.5; 95% CI, 0.88‐2.5). Older women taking tamoxifen appeared to be at higher risk than younger women during the first 2 years of exposure. CONCLUSIONS: The findings of the current study suggest that the first 2 years after the initiation of tamoxifen therapy may be the most crucial time for monitoring DVT/PE risk, particularly in older women. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Cited by
Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
Horsted, F., West, J., & Grainge, M. J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001275 · Cited by 565
Cronin-Fenton, D. P., Søndergaard, F., Pedersen, L. A., Fryzek, J. P., Cetin, K., Acquavella, J., Baron, J. A., & Sørensen, H. T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605883 · Cited by 372
Self-citationComprehensive review of cardiovascular toxicity of drugs and related agents
Mladěnka, P., Applová, L., Patočka, J., Costa, V. M., Remiao, F., Pourová, J., Mladěnka, A., Karlíčková, J., Jahodář, L., Vopršalová, M., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21476 · Cited by 310
Young, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
Metadata
- Authors
- Hernandez, R. K., Sørensen, H. T., Pedersen, L., Jacobsen, J., & Lash, T. L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-06-30
- Volume
- 115
- Issue
- 19
- Pages
- 4442-4449
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1970642927
- Cited by
- 185
- References
- 1
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: A Danish population‐based cohort study. https://app.cochat.ai/papers/10.1002/cncr.24508
- The paper
- Hernandez, R. K., Sørensen, H. T., Pedersen, L., Jacobsen, J., & Lash, T. L. (2009). Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: A Danish population‐based cohort study. Cancer. https://doi.org/10.1002/cncr.24508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.